Pyoderma gangrenosum
Tha Pyoderma gangrenosum na ghalar craiceann tearc, inflammatory, far a tha pustules no nodules goirt a’ fàs ann an ulceran a thèid a leudachadh le àm. Chan eil Pyoderma gangrenosum contagach. Faodaidh an leigheas a bhith a’ gabhail a-steach corticosteroids, ciclosporin no antibodies monoclonal. Ged a dh’ fhaodadh e buaidh a thoirt air daoine aig aois sam bith, tha e a’ bhuaidh gu h-àraidh air daoine anns na 40an is 50an aca.
☆ AI Dermatology — Free Service
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Air cùis neach le colitis ulcerative.
relevance score : -100.0%
ReferencesIs e suidheachadh craiceann tearc a th’ ann an Pyoderma gangrenosum a dh’adhbhraicheas ulcair goirt le oirean dearg no purpaidh. Tha e air a chomharrachadh mar ghalar sèid agus tha e na phàirt de bhuidheann ris an canar dermatoses neutrophilic. Tha adhbhar Pyoderma gangrenosum iom-fhillte, a’ toirt a-steach duilgheadasan le dìonachd dhùthchasach agus atharrachail ann an daoine a tha dualtach gu ginteil. O chionn ghoirid, tha luchd-rannsachaidh air fòcas a chuir air folliculan fuilt mar thoiseach tòiseachaidh na ghalair.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Is e suidheachadh craiceann ainneamh a tha ann ann an Pyoderma gangrenosum a dh’adhbhraicheas ulcair gu math goirt. Ged nach eil sinn gu tur a’ tuigsinn adhbhar na ghalair, tha fios againn gu bheil e a’ toirt a-steach gnìomhachd nas motha cuid de cheallan dìon. Chan eil làimhseachadh an galair fhathast furasta. Tha diofar dhrogaichean ann a chuireas stad air an t-siostam dìon no a dh’atharraicheas a ghnìomhachd. Còmhla ri sin, bidh sinn cuideachd a' cuimseachadh air làimhseachadh lotan agus stiùireadh pian. Is e corticosteroids agus cyclosporine gu tric a’ chiad roghainn airson làimhseachadh, ach o chionn ghoirid, chaidh barrachd rannsachadh a dhèanamh air cleachdadh leigheasan bith‑eòlais leithid bacairean TNF‑α. Tha na bith‑eòlais sin a’ sìor fhàs nas fheàrr, gu sònraichte ann an euslaintich le suidheachaidhean sèid eile, agus thathas gan cleachdadh nas trice ann am pròiseas galair.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
